Clinical Trials

Sponsor: Amgen, Inc.

Sponsor Study ID: 20200439

Study Title: A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination with AMG 404 in Subjects with Small Cell Lung Cancer (SCLC)

NCT Number: NCT04885998

Phase: I

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Lung

Study Objectives: The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of AMG 757 in combination with AMG 404.

Study Documents    
(MUSC NetID required for document access)